Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
This is according to the largest-ever analysis of the treatment cascade among people tested for hepatitis C.
Preliminary results from an ongoing trial found that half of the participants could take less than 12 weeks of a cure regimen.
In the first five months of 2018, 803 HCV-positive organs were transplanted across the United States.
Research suggests that individuals receiving opioid replacement therapy have a better chance of beating hep C through this method.
Medi-Cal will soon begin providing treatment access to almost all state-insured patients living with the virus.
More proof that filing treatment access lawsuits can pay off for people with HCV.
All the major world organizations, shareholders, some countries, and the state of New York are committed to the elimination of hepatitis C.
The triple-drug combo would be the first once-daily, single-tablet regimen for those with all genotypes who’ve failed a previous treatment.
A regimen of standard oral drugs bookended by an injectable treatment has shown promise in curing hepatitis C in just four weeks.
Real-world results of eight weeks of the hepatitis C virus treatment Harvoni (ledipasvir/sofosbuvir) are excellent.
Before now, the VA said it could only afford to treat the sickest HCV-positive people in its health care system.
However, the drugs will only be made available to patients who already have advanced liver disease.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.